PTAB Mostly Rejects Lupin's AIA Review Of HIV Drug Patent
The Patent Trial and Appeal Board has partially nixed Lupin Limited's bid for an America Invents Act review of certain claims of a patent covering the anti-HIV drug Lexiva, saying that...To view the full article, register now.
Already a subscriber? Click here to view full article